Trial of peptide-centered SARS-CoV-2 T-cell activator in B-cell poor people
  • Reading time:7 min(s) read

A latest part 1/2 research underneath overview on the Nature Portfolio journal and posted to the Research Square* preprint server demonstrated {that a} peptide-centered extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell activator, CoVac-1, was environment friendly in B-cell poor folks.

Study: Phase I/II trial of a peptide-based COVID-19 T-cell activator in sufferers with B-cell deficiency. Image Credit: Kateryna Kon / Shutterstock


The SARS-CoV-2-induced coronavirus illness 2019 (COVID-19) pandemic prompted the invention of quite a few vaccinations that safeguard billions of people from the illness’s extreme course, primarily by means of the technology of humoral or antibody-triggered immunity. T-cell immunity is important for controlling SARS-CoV-2 an infection, particularly in people who can’t generate a humoral immune response to a prophylactic vaccination or pure an infection. Individuals with inherited B-cell deficiency and most cancers sufferers with treatment- or disease-linked B cell discount fall into this class. T cells are essential for COVID-19 outcomes and SARS-CoV-2 immunity upkeep along with B cell-driven humoral immunity.

CoVac-1, a peptide-based T-cell activator comprising of SARS-CoV-2 T-cell epitopes obtained from a number of viral proteins, coupled with the toll-like receptor 1 and a couple of (TLR 1/2) agonist XS151, had a good efficacy and security profile in a part 1 trial amongst wholesome adults contemplating the induction of COVID-19-specific T-cell responses, in accordance with the authors of the present research. This T cell response was superior to these induced by COVID-19 or presently authorised SARS-CoV-2 vaccines. 

CoVac-1 includes varied SARS-CoV-2 human leukocyte antigen (HLA)-DR T cell epitopes generated from distinct SARS-CoV-2 proteins, similar to nucleocapsid (N), spike (S), membrane (M), envelope (E), open studying body 8 (ORF 8). Hence, CoVac-1 stimulates T-cell immunity autonomous of present SARS-CoV-2 variants of concern (VOCs).

About the research

In the present research, the researchers ran a Phase 1/2 open-label CoVac-1 experiment enrolling 54 people with acquired or congenital B-cell deficiency who acquired a single subcutaneous CoVac-1 dose in Germany. The research’s main purpose was immunogenicity by way of CoVac-1-triggered T-cell responses until day 28; the secondary goal was security until day 56. In addition to B-cell deficiency, half of the sufferers had CD4 + T cell counts of lower than 500/µl, highlighting the trial inhabitants’s extreme immunodeficiency.

The group evaluated the information on antagonistic occasions from the sufferers. T-cell reactions towards the six SARS-CoV-2 HLA-DR CoVac-1 T cell epitopes have been measured using enzyme-linked immunosorbent spot (ELISPOT) evaluations to find out immunogenicity. T-cell responses have been measured in all eligible topics at baseline/day 1, day 7, 14, and 28 following receiving CoVac-1.


The research outcomes confirmed that 94 sufferers with acquired or congenital B-cell deficiency have been screened at three analysis websites in Germany from 6 July 2021 to 13 January 2022. In addition, CoVac-1 was given to 54 sufferers, 14 within the Phase 1 security run-in and 40 within the Phase 2 portion of the experiment. 

CoVac-1-induced T-cell responses with regard to Omicron variants and in comparison with mRNA vaccine- or infection-induced T-cell response. (a) CoVac-1-specific T-cell responses assessed ex vivo in research sufferers (day 28) in comparison with spike-specific T-cell responses previous to CoVac-1 administration in sufferers after second or third vaccination with authorised mRNA vaccines (n = as indicated). (b) Intensities of P3_spike-induced IFN‑g T-cell responses assessed ex vivo in research sufferers (n = as indicated) previous to and on day 28 after CoVac-1 administration. (c) Exemplary ex vivo ELISPOT assays of 1 research affected person (UPN12), with pre-existing T-cell responses to P3_spike, for the six CoVac-1 peptides on day 1 (white) and day 28 (gray). The intensities of IFN‑g T-cell responses are depicted as calculated spot counts (imply spot rely of technical replicates minus the respective adverse management). (d) Color-coded mutations described for SARS-CoV-2 Omicron variants are proven along with CoVac-1 peptides (orange). Positive T-cell responses to particular (spec) and cross-reactive (cross) T-cell epitope compositions (ECs) in (e) immunocompetent HCs (CoVac-1, spec EC, cross EC, n = as indicated)10,11 and (f) immunocompetent HCs with out anti-SARS-CoV-2-antibody response after an infection (CoVac-1, spec EC cross EC, n = as indicated) in comparison with optimistic IFN-g T-cell responses in research sufferers assessed ex vivo (B-CoVs, n = as indicated, day 28). (a,b,e,f) The depth of IFN‑g T-cell responses is depicted as calculated spot counts (imply spot rely of technical replicates minus the respective adverse management). Box plots or mixed box-line plots present median with twenty fifth or seventy fifth percentiles, and min/max whiskers. (c) Bars with imply, SD and single information factors. no., quantity; EC, epitope composition; HCs, wholesome COVID-19 convalescents; ORF, open studying body; pos, optimistic.

Details on unsolicited and solicited antagonistic occasions have been obtainable for each participant by way of diary playing cards for 28 days following CoVac-1 administration and security checkups until day 56. No topic dropped out of the research attributable to negative effects. The authors didn’t observe CoVac-1-associated grade 4 or vital negative effects. The anticipated formation of native granuloma was seen in 94% of research contributors. On the opposite hand, systemic reactogenicity was primarily nonexistent or gentle. 

On day 28, SARS-CoV-2-selective T cell reactions have been generated in 86% of the themes and oriented to quite a few CoVac-1 peptides, with a mean of 4 out of six peptides recognized by the sufferers’ T cells. These responses weren’t influenced by any present SARS-CoV-2 Omicron mutants and have been regulated by multipurpose T-helper 1 (Th1) CD4+ T cells. These Th1 cells had positivity for interferon γ (IFN-γ), CD107a, interleukin-2 (IL-2), and tumor necrosis issue (TNF).

According to subgroup evaluation, on day 28, these with acquired B-cell deficit had superior response charges and percentages of CoVac-1-triggered T cells than people with congenital B-cell deficiency. There was no discernible variance within the frequency and energy of CoVac-1-generated T-cell responses amongst most cancers sufferers receiving anti-CD20 remedy and those that didn’t. 

Further, in B-cell missing people and immunocompetent seroconverted/non-seroconverted COVID-19 recovered topics, CoVac-1-generated T-cell responses outperformed S-specific T-cell responses following vaccination with messenger ribonucleic acid (mRNA) vaccines. CoVac-1 was additionally capable of improve pre-existing S-specific T-cell responses.

None of the contributors demonstrated any humoral immune response to SARS-CoV-2 at analysis inclusion, regardless of receiving greater than two doses of authorised COVID-19 vaccines. However, low-degree SARS-CoV-2 anti-S immunoglobulin G (IgG) antibodies technology was seen in sufferers upon a single CoVac-1 dose administration, regardless of frequently adverse leads to serial SARS-CoV-2 polymerase chain reactions (PCRs).


The current research reported the immunogenicity, reactogenicity, and security of CoVac-1 within the at-risk cohorts with acquired or congenital B-cell deficiency. Even on this drastically immunocompromised pattern inhabitants, this investigation verified the wonderful security document and demonstrated sturdy de novo activation of T-cell responses following a single CoVac-1 dose. 

The authors concluded that with an excellent security attribute, CoVac-1 elicits broad and sturdy T-cell responses in people with antibody/B cell deficit, no matter current SARS-CoV-2 VOCs. The present information help transferring ahead of CoVac-1 to a pivotal Phase 2/3 effectiveness and security research. An extended-term Phase 2/3 efficacy analysis utilizing CoVac-1 is now being ready to find out which phenotypes and frequencies of T cells are wanted to assist deal with COVID-19.

*Important discover

Preprints with Research Square publish preliminary scientific reviews that aren’t peer-reviewed and, due to this fact, shouldn’t be thought to be conclusive, information scientific apply/health-related habits, or handled as established data.

Journal reference:

  • Juliane Walz, Jonas Heitmann, Claudia Tandler et al. Phase I/II trial of a peptide-based COVID-19 T-cell activator in sufferers with B-cell deficiency, 02 June 2022, PREPRINT (Version 1) obtainable at Research Square,,

If you are interested in working in a distraction free environment, visit our site Blissful Noises where we provide various sounds and features to help you focus or relax.